Amgen Inc.'s first quarter earnings fell short of Wall Street estimates, with the Thousand Oaks, Calif.-based company posting $4.24 billion in revenues, shy of the $4.38 billion expected by consensus. Read More
To spur innovation in biopharma and other industries, Congress must make it a national priority, according to the Congressional Budget Office (CBO). Read More
With more than 15,000 patients in the U.S. waiting for a liver, and nearly 100,000 for a kidney, the most dramatic need for artificial organs is for transplant. Read More
CHICAGO – Innovation was the topic of a heavily attended supersession at BIO 2013 that featured presenters from big pharma, academia, federal agencies and the venture capital (VC) community but, interestingly, no biotechs. Read More
CHICAGO – Navigating the patent landscape in developing countries is hard enough, and made even trickier by such moves as the one made earlier this month by El Salvador, which passed a law that cut prices by at least 30 percent for more than 6,000 medicines, and as much as 60 percent for the most common therapies. Read More
CHICAGO – Introducing a panel on new approaches to vaccine development at the BIO International Conference in Chicago, Inovio Pharmaceuticals Inc. Chief Operating Officer Niranjan Sardesai quoted a well-known proverb, "Give a man a fish, and you feed him for a day. Teach a man to fish, and you feed him for a lifetime," to illustrate the difference between drugs and vaccines. Read More
DUBLIN, Ireland – Two days after the board of Elan Corp. plc unanimously rejected Royalty Pharma's $7.3 billion takeover offer, CEO Kelly Martin set out, as best he could, the contours of the company's M&A strategy during a first-quarter results call with analysts Wednesday. Read More
• Genticel SA, of Toulouse, France, raised €18.2 million (US$23.6 million) in a private equity round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials. Read More
• Addex Therapeutics, of Geneva, said regulatory authorities in the Netherlands gave approval to start in the first half of this year a Phase I study of ADX71441, a GABA-B receptor positive allosteric modulator, for Charcot-Marie-Tooth1A (CMT1A) neuropathy and other disease indications. Read More
• Chimerix Inc., of Durham, N.C., said that its Phase III SUPPRESS trial of CMX001 for cytomegalovirus following allogeneic hematopoietic stem cell transplant now has a finalized design for population, endpoints, dosing and duration of therapy. The details were settled following an end-of-Phase II meeting with the FDA in May 2012. Read More
• GE Healthcare, of Chalfont St. Giles, UK, and Eisai Inc., of Woodcliff Lake, N.J., inked a research collaboration agreement for use of the GE Healthcare investigational PET amyloid imaging agent [18]flutemetamol to help select patients for a Phase I trial testing Eisai's E2609, a BACE inhibitor for the potential treatment of Alzheimer's disease. Read More
